In Drugs for Rare Diseases: Early Commercial Thinking = Future Commercial Success
Rare Diseases: Growing Business Opportunity
Orphan drugs typically target diseases with fewer than 200,000 patients and cost over $100,000 per year per patient. Drugs targeting really small groups of patients (ultra-orphan or rare diseases) often cost much more.
As a result, pharma and biotech’s interest in developing these drugs continues to grow.
Download this whitepaper now to find out more about:
-
Why the Commercial Perspective Matters
-
Lack of Disease Awareness = Lost Revenues
-
Noise Precedes Signal vs Signal Precedes Noise
-
Zero Moment of Truth
-
Thinking Beyond The Pill
-
Endpoints Drive Endgame
-
Payer Pushback
Get your copy now >